Oncopeptides Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
It looks like Oncopeptides isn’t giving up on their drug melflufen. The drug in combination with dexamethasone(anti inflammatory Glucocorticoids) seems to show better progression free survival than pomalidomide(another approved drug for cancer patients) statically yet they had still some safety issues which they are trying to tackle by dose adjustments. We saw somehow similar situation for Sutro’s ADC so the relevance of these data in comparison to THTX’s PDC is once they get that MTD coupled with some efficacy results now or later on as they will try the drug on more patients with various cancers they might have to adjust the dosage in case they face similar safety issues as long as the drug is effective in lower doses.
Point is the trial process is and will be fluid so that RP2D for Phase1b and behind can be adjusted later on based on both safety and efficacy results.
Even with those results their SP appreciated some 16%.